

Influenza:

NICD recommendations for the diagnosis, management, prevention and public health response

April 2025

Version 1.7 (22 April 2025)**Authors (Alphabetical order):**

Lucille Blumberg
Cheryl Cohen
Halima Dawood
Shabir Madhi
Alan Karstaedt
Kerrigan McCarthy
Jocelyn Moyes
Jeremy Nel
Adrian Puren
Wayne Ramkrishna
Gary Reubenson
Florette Treurnicht
Ebrahim Variava
Anne von Gottberg
Nicole Wolter
Sibongile Walaza (prepared initial draft)
Heather J Zar

Acknowledgements

Physicians, paediatricians, neonatologists, infectious disease specialists, public health specialists and virologists who provided valuable input in the drafting of these guidelines

Version 1.5

Summary of changes:

Date reviewed	Reviewed by	Summary of changes
22 April 2025	S Walaza	This report updates the 2024 influenza guidelines, the following updates are included • Influenza vaccine composition for 2025 influenza season • Added summary of South Africa 2024 influenza season • Removed sections on COVID-19 • Added information on identifying patients with non-severe influenza at high risk of progressing to severe illness (i.e. hospitalization or mortality) • Updated recommendation on antiviral therapy • Added paragraph for clinicians to use opportunities to vaccinate
19 April 2024	S Walaza	• Updated influenza vaccine composition for 2024 influenza season • Added summary of 2023 season • Updated section on COVID-19 vaccines
28 April 2023	S Walaza	• Updated influenza vaccine composition for 2023 influenza season • Added paragraph on zoonotic influenza • Removed inhaled Zanamivir as a treatment option due to change in WHO guidelines • Added summary of 2022 influenza season • Reduced contagious period for SARS-CoV-2 from at least 7 days to at least 5 days
22 April 2022	S Walaza	• Updated influenza vaccine composition for 2022 influenza season

		• Guidance on the administration of influenza vaccines with other vaccines has been expanded to include COVID-19 vaccines • Added information on influenza epidemiology • Added information on use of corticosteroids for severely ill patients with influenza and COVID-19
12 April 2021	S Walaza	• Added data on annual national burden of medically and non-medically attended influenza-associated mild, severe-non-fatal and fatal illness among potential target groups in South Africa • Added updated influenza-burden estimates in South Africa • Updated influenza vaccine composition for 2021 influenza season • Updated information on quadrivalent influenza vaccine • Added section on administration of influenza vaccine and SARS-CoV-2 vaccine • Added procedures for collecting mid-turbinate nasal swabs • Added information on influenza and SARS-CoV-2 co-circulation and implications for testing and public health response • Added summary of influenza and COVID-19 clinical presentation
2 April 2020	J Moyes	Updated influenza vaccine composition for 2020 influenza season Updated groups recommended to receive vaccine

		New guidance on influenza vaccine and COVID and quadrivalent influenza vaccines
6 June 2019	S Walaza	Updated influenza vaccine composition for 2019 influenza season
13 April 2018	S Walaza	Updated influenza vaccine composition for 2018 influenza season Updated influenza burden estimates

Disclaimer:

The information contained in this document, be it guidelines, recommendations, diagnostic algorithms or treatment regimens, is offered in the public interest. To the best of the knowledge of the writing team, the information contained in these recommendations is correct at the time of publication. Implementation of any aspect of these guidelines remains the responsibility of the implementing agency in so far as public health liability resides, or the responsibility of the individual clinician in the case of diagnosis or treatment.

Quick Reference Guide - Influenza

Categories of influenza- Page 10

Non-severe/Uncomplicated influenza: ILI (Influenza-like illness) may present with fever, cough, sore throat, coryza, headache, malaise, myalgia, arthralgia and sometimes gastrointestinal symptoms, but without any features of complicated influenza.

Severe/Complicated influenza: Influenza infection requiring hospital admission and/or with symptoms and signs of lower respiratory tract infection (hypoxaemia, dyspnoea, tachypnoea, lower chest wall indrawing and inability to feed), central nervous system involvement and/or a significant exacerbation of an underlying medical condition.

Risk groups for severe/complicated influenza disease -Page 11-12

- Persons aged ≥ 65 years
- People living with HIV
- Persons of any age with chronic diseases:
 - Pulmonary diseases (e.g. asthma, COPD)
 - Immunosuppression (e.g. persons on immunosuppressive medication, malignancy)
 - Cardiac diseases (e.g. congestive cardiac failure), except for hypertension
 - Metabolic disorders (e.g. diabetes mellitus)
 - Renal disease
 - Hepatic disease
 - Neurologic and neurodevelopmental conditions
 - Haemoglobinopathies (e.g. sickle cell disease)
- Pregnant women and women up to 6 weeks postpartum
- Individuals with tuberculosis
- Persons aged ≤ 18 years receiving chronic aspirin therapy
- Persons who are morbidly obese (i.e. BMI ≥ 40).
- Young children (particularly < 1 year of age)

Groups targeted for Department of Health 2025 influenza vaccination campaign - Page 22

- Individuals aged ≥ 65 years
- Individuals with chronic pulmonary (including tuberculosis, asthma and COPD), cardiovascular and renal diseases, diabetes and individuals with immunosuppressive conditions (e.g. living with HIV and AIDS and malignancy)
- Pregnant women at all stages of pregnancy, including women in the postpartum period
- Healthcare workers

Recommended inactivated influenza vaccine (IIV) formulation for 2025 - Page 21-22

- an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
 - an A/ Croatia/10136RV /2023 (H3N2)-like virus;
 - a B/Austria/1359417/2021 (B/Victoria lineage) like-virus; and
 - B/Phuket/3073/2013-like (B/Yamagata lineage) virus*
- *included in the quadrivalent vaccine, available in private sector

Treatment of influenza - Page 17-19

Neuraminidase inhibitors (oseltamivir) and cap-dependent endonuclease inhibitors (baloxavir marboxil) are recommended for the treatment of any patient with suspected or confirmed influenza who:

- has severe/ complicated illness (hospitalised patients)
- is at very high risk for influenza hospitalisation or mortality

Treatment should be started early, ideally within 48 hours of symptom onset.

Dosage of influenza vaccine - Page 23-24

- ≥ 9 years —0.5ml IMI single dose (TIV/QIV)
 - 3 years to 8 years - 0.5ml IMI 1 or 2 doses (TIV/QIV)*
 - 6 months to 2 years - 0.25ml IMI 1 or 2 doses (TIV)*
 - 6 months to 2 years - 0.5ml IMI 1 or 2 doses (QIV)*
- *2 doses should be administered ≥ 1 month apart during 1st year of vaccination, thereafter one dose.

Additional questions from health professionals can be directed to: for clinical support - National Institute for Communicable Diseases (NICD) **Hotline:** 080 021 2552, for laboratory support - NICD, Centre for Respiratory Diseases and Meningitis: **011 386 6410** sibongilew@nicd.ac.za | cherylc@nicd.ac.za | nicolew@nicd.ac.za

1. Introduction

Seasonal influenza

Influenza, commonly known as the “flu”, is an acute infection of the respiratory tract caused by influenza viruses. There are three types of seasonal influenza viruses – A, B and C. Influenza A viruses are further categorised into subtypes, and influenza B into lineages. Influenza viruses are genetically dynamic and evolve in unpredictable ways. Influenza viruses are further classified based upon antigenic properties. Humoral immunity to influenza viruses is generally thought to be strain-specific and acquired through infection and/or vaccination. Seasonal influenza epidemics can be caused by evolving viruses that are antigenically distinct from previously circulating viruses to which a population has some immunity; this is known as antigenic drift. Uncommonly, a completely new strain of influenza will emerge to which there is little or no existing immunity, this is known as antigenic shift and such novel strains can give rise to influenza pandemics.

Zoonotic influenza

Influenza viruses circulating in animal species such as avian influenza A virus subtypes A(H5N1), A(H5N6), A(H7N9), A(H7N7) and A(H9N2) and swine influenza A virus subtypes A(H1N1), A(H1N2) and A(H3N2) can sporadically be transmitted to humans, causing mild to very severe disease and may contribute to the emergence of pandemic strains. Human infections are primarily acquired through direct contact with infected animals or contaminated environments. Human infection can range from asymptomatic to conjunctivitis or mild upper respiratory tract illness (cough with or without fever) to rapid progression to severe pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, sepsis with shock and even death. Currently, zoonotic influenza is rare as it requires close contact with animals such as pigs or birds, and human-to-human transmission of zoonotic influenza is very uncommon. Additional information on avian influenza can be accessed here [Avian influenza guidance](#).

2. Epidemiology

Influenza virus infections cause substantial annual morbidity and mortality worldwide, including South Africa [1-4]. Annual influenza epidemics result in an estimated three to five million cases of severe illness, and about 290 000-650 000 deaths globally [4]. Influenza is an important cause of pneumonia or lower respiratory tract infection (LRTI) and approximately 8-10% of all patients with pneumonia test positive for influenza [5].

The burden of influenza in sub-Saharan Africa (and specifically in South Africa) is substantial, with some studies suggesting elevated influenza-associated mortality rates compared to other regions [6, 7]. During the influenza season (usually between May and September) in South Africa, approximately 14% of inpatients with lower respiratory tract infection and 25% of patients with influenza-like illness will test polymerase chain reaction (PCR) positive for influenza. A modelling study from South Africa using case-based and ecological data estimated that during 2013-2015 on average 10 737 847 (19.8%) South Africans had influenza-associated illness annually of which 10 598 138 (98.7%) were mild, 128 173 (1.2%) were severe and 11 536 (0.1%) were fatal.[8] The highest number of mild cases occurred among individuals aged 5–24 years (5 745 544, 54.2%). An estimated 4 195 (36.1%) of influenza-associated deaths were in individuals aged ≥ 65 years. Overall, the rates of influenza-associated mild illness were highest among individuals aged 5-24 years (28 935.2 per 100 000 individuals in the population), rates of influenza-associated severe non-fatal illness were higher among individuals aged <1 year (1550.9 per 100 000 individuals in the population) and ≥ 65 years (761.3 per 100 000 individuals in the population), and rates of influenza-associated deaths were higher among infants <1 year (80.3 per 100 000 individuals in the population) and persons aged ≥ 65 years (137.9 per 100 000 individuals in the population) [8]. In South Africa, among individuals aged ≥ 5 years, an estimated 30% of influenza-associated deaths are in people living with HIV (PLWH) [9]. Pregnant women also constitute an important risk group for influenza-associated mortality. Among an estimated 646 - 1 428 seasonal influenza-associated deaths in women of childbearing age in South Africa, the majority ($\sim 90\%$) occurred in PLWH and the influenza-associated mortality was three-fold higher (relative risk (RR) 2.8, 95% confidence interval (CI) 1.7 – 3.9) in pregnant compared with non-pregnant women. [10]

The highest rates of influenza-associated hospitalisation are in those aged ≥ 65 years, PLWH and children aged <5 years (in particular children <1 year). [1, 9, 11-13]. Data from South Africa showed that extremes of age (<6 months [adjusted odds ratio (aOR), 37.6], 6–11 months [aOR, 31.9], 12-23 months [aOR, 22.1], 24–59 months [aOR, 7.1], and ≥ 65 years [aOR, 40.7] compared to those aged 5-24 years), underlying medical conditions (aOR, 4.5), living with HIV (aOR, 4.3) and history of working in a mine (aOR, 13.8) were significantly associated with increased risk of influenza-associated hospitalisation [14]. Influenza infection may trigger exacerbations of diabetes, pulmonary (e.g. asthma) or cardiovascular disease. For this reason, people with underlying chronic medical conditions are at high risk of influenza complications, often resulting in hospitalisation and even death. Surveillance data from South Africa showed that having underlying illnesses (other than HIV) was a risk for influenza-associated mortality (odds ratio (OR) 2.9, 95% CI 1.2 - 7.3) [1]. Individuals

with tuberculosis may also be at increased risk of influenza-associated death [15, 16]. The burden of hospitalisations and deaths due to influenza can vary substantially from year to year depending on the transmission and virulence characteristics of the circulating strain(s).

A study in South Africa, assessing the mean annual national burden of medically and non-medically attended influenza-associated mild, severe-non-fatal and fatal illness among potential target groups for influenza immunisation in South Africa during 2013-2015, reported that rates of influenza-associated illness were highest in children aged 6-59 months (23,983 per 100,000 population) for mild illness, in pregnant women (930 per 100,000 population) for severe-non-fatal illness and in individuals aged ≥ 65 years (138 per 100,000 population) for fatal illness.[17]

In tropical areas, influenza occurs throughout the year. In temperate areas, like in South Africa, influenza is highly seasonal and typically occurs during winter months. In 2024, influenza detections were made throughout the year, the influenza season started in week 17 (week starting 22 April 2024), peaked in week 23 (week starting on 3 June 2024) and ended in week 41 (week starting 7 October 2024). The first peak of the season was dominated by influenza A(H1N1)pdm09 when influenza transmission and morbidity were at moderate and high levels, in the outpatient influenza-like illness (ILI) and hospitalised Pneumonia Surveillance programmes respectively. A second smaller increase predominated by B/Victoria was observed, peaking in week 35 (week starting 26 August 2024) [18].

Microbiology, pathology and pathogenesis

Human influenza viruses are single-strand RNA viruses that belong to the Orthomyxoviridae family, consisting of the genera influenza A, B, and C viruses. Only influenza A and B viruses cause epidemics in humans. Based on their main antigenic determinants, the haemagglutinin (H or HA) and neuraminidase (N or NA) transmembrane glycoproteins, influenza A viruses are further subdivided into 18 H (H1–H18) and 11 N (N1–N11) subtypes, but only 3 haemagglutinin subtypes (H1, H2 and H3) and two neuraminidase subtypes (N1 and N2) have circulated consistently in the human population and are responsible for annual epidemics.

HA and NA are critical for pathogenesis, and are major targets for the neutralizing antibodies of acquired immunity to influenza. Influenza B viruses are classified into lineages, B/Yamagata and B/Victoria. B/Yamagata has not been detected after March 2020. Influenza C viruses are detected less frequently and usually causes mild infections, thus do not have public health importance. Influenza D viruses primarily affect cattle and are not known to infect or cause illness in people.

3. Transmission

Influenza viruses are spread from person-to-person. They can be transmitted by exposure to infectious droplets expelled by coughing or sneezing that are then inhaled by others, or can contaminate hands or other surfaces. The typical incubation period for influenza is 1-4 days (average 2 days). Most persons ill with influenza shed virus (i.e. may be infectious) from a few days before symptoms begin through 5-7 days after illness onset. However, very young children can be infectious for >10 days after illness onset; adults with severe disease (e.g. viral pneumonia) may also shed virus for >10 days, and severely immunocompromised persons can shed virus for even longer [19]. Children have the highest rates of seasonal influenza infection and illness in this group can amplify viral transmission in the community.

4. Clinical presentation and risk factors for influenza

Infection with influenza viruses has a wide range of clinical presentations, ranging from asymptomatic infection to severe illness and death depending on the characteristics of both the virus and the infected person. In the majority of people, influenza is an uncomplicated illness that is characterised by sudden onset of constitutional and respiratory symptoms such as fever, myalgia, cough, sore throat, rhinitis and headache. Uncomplicated influenza illness resolves after 3-7 days, although cough and malaise can persist for >2 weeks. Influenza may be associated with more severe complications including: influenza-associated pneumonia/ LRTI, secondary bacterial or viral infection (including pneumonia, sinusitis and otitis media), multi-organ failure, and exacerbations of underlying illnesses (e.g. pulmonary and cardiac illness). Rare complications include encephalopathy, encephalitis, transverse myelitis, myocarditis, pericarditis and Reye syndrome. For purposes of clinical management, influenza disease can be categorised as follows [20]:

- **Non-severe /Uncomplicated influenza:** ILI (Influenza-like illness) may present with fever, cough, sore throat, coryza, headache, malaise, myalgia, arthralgia and sometimes gastrointestinal symptoms, but without any features of complicated influenza.
- **Severe/ Complicated influenza:** Influenza requiring hospital admission and/or with symptoms and signs of lower respiratory tract infection (hypoxaemia, dyspnoea, tachypnoea, lower chest wall indrawing and inability to feed), central nervous system involvement and/or a significant exacerbation of an underlying medical condition.

4.1 Risk factors for severe/complicated influenza

Certain groups of patients are at higher risk of developing severe or complicated disease following influenza virus infection. However, influenza virus infection can result in severe/complicated illness in previously healthy individuals. Similar to other studies showing increased risk of severe influenza-associated illness in certain individuals, [1, 2, 6, 9, 10, 15, 16, 21, 22] a study from South Africa found that younger and older age (<5 years, in particular children <1 year, and ≥65 years) and the presence of chronic underlying medical conditions, HIV infection and pregnancy were associated with increased risk of influenza-associated hospitalisation[14]. In addition, PLWH with severe immunosuppression compared to those with mild immunosuppression had three times increased odds of influenza-associated hospitalisation [14].

4.1.1 Risk groups for severe/complicated influenza disease include:

- Persons aged ≥65 years
- People living with HIV [14, 23]
- Persons of any age with chronic disease, including:
 - Pulmonary diseases (e.g. asthma, COPD)[24]
 - Immunosuppression (e.g. persons on immunosuppressive medication, malignancy)
 - Cardiac diseases (e.g. congestive cardiac failure), except for hypertension[24]
 - Metabolic disorders (e.g. diabetes mellitus)[25]
 - Renal disease
 - Hepatic disease
 - Certain neurologic and neurodevelopmental conditions, including: disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy (seizure disorders), stroke, mental retardation, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury.
 - Haemoglobinopathies (e.g. sickle cell disease)
- Pregnant women and women up to 6 weeks postpartum
- Individuals with tuberculosis[15, 16, 26]
- Persons aged ≤18 years receiving chronic aspirin therapy
- Persons who are morbidly obese (i.e. BMI ≥40)[27]
- Children aged <5 years (particularly <1 year of age)

4.1.2 Identifying patients with non-severe influenza at high risk of hospitalization or mortality

In an attempt to identify the most significant risk factors for non-severe influenza cases developing severe disease, the WHO commissioned a systematic review of observational studies. Risk factors were considered significant in predicting risk of hospitalisation or mortality in patients with non-severe illness if odds ratios were > 2.0 and level of confidence was at least moderate. Age ≥65 years, immunocompromising conditions, cardiovascular disease, neurological diseases and chronic respiratory conditions were significant for admission. In addition, pregnancy, diabetes and malignancy were identified as important but less impactful (OR 1.7-2.0 and moderate certainty of confidence) [28]. Age ≥65 years, Charlson comorbidity index (per point increase) and smoking were associated with increased odds of all-cause mortality in patients with non-severe illness [28].

5. Laboratory Diagnosis

Laboratory testing of non-severe or uncomplicated illness (patients who fit the ILI case definition) is **NOT** routinely recommended, as it provides no advantage in the management of individual patients. Testing can be considered for the following patients:

- Patients who meet the criteria for severe or complicated influenza, where a laboratory diagnosis will assist in patient management.
- Clusters of cases where a diagnosis of the cause of the outbreak is needed (e.g. within institutions such as healthcare facilities, nursing homes). First 2-3 cases to be tested, thereafter testing not required.
- In cases where avian influenza is suspected (e.g. among individuals with exposure to birds and animals)

Important note: Initial treatment decisions should be based on clinical presentation and should NOT be delayed pending laboratory confirmation of influenza.

These recommendations for laboratory testing do not apply to surveillance activities (e.g. Viral Watch, influenza-like illness (ILI), pneumonia surveillance programme), and testing should continue as guided by those individual surveillance programmes.

5.1 Laboratory testing for influenza

The NICD does not offer routine diagnostic testing, including for influenza, outside of established surveillance programmes at specific sites. Diagnostic capacity to test for influenza viruses is established in various National Health Laboratory service (NHLS) and private-sector laboratories

throughout the country. Under special circumstances (e.g. outbreak investigation), NICD will provide support for testing. Requests for testing at NICD should be discussed with the doctor on call, through the **NICD Hotline** –0800 21 2552 before samples are collected.

In line with WHO recommendations, molecular diagnostics (real-time multiplex PCR for influenza A and B viruses) are currently the method of choice for influenza virus detection. While specificity is high, the sensitivity of currently available rapid-point-of-care or immunofluorescence tests designed for direct detection of influenza A viruses is low (59%-93%) and therefore they are not recommended for diagnostic purposes. A negative Rapid Influenza Diagnostic Test (RIDT) result does NOT exclude influenza infection, and should not preclude starting empiric antiviral treatment where clinical indications exist.

5.2 Specimen collection, storage and transportation

Combined nasopharyngeal and oropharyngeal swabs in universal transport medium (UTM) are the preferred specimens for testing. However, when aerosolisation of respiratory samples is to be avoided and/or swabs are limited, a mid-turbinate nasal swab or oropharyngeal swab in place of a nasopharyngeal swab can be used. Flocked swabs should be used to collect specimens as they provide a better yield on PCR [29]. Dacron or rayon swabs may be used if flocked swabs are not available. Cotton wool budded swabs are not recommended. Once collected, these samples should be placed in viral or universal transport medium and transported in a cooler box with ice packs to the testing laboratory. The specimens must be refrigerated at 2-8°C if transport is expected to be delayed. If the specimen(s) cannot be shipped within 72 hours of collection, they should be kept frozen at -70°C. Avoid repeated freezing and thawing of specimens.

For specimens submitted to NICD to test for influenza, a completed specimen request form (follow link, [CRDM-specimen-submission-form](#)) with patient name, health facility (where appropriate), healthcare worker's name and contact numbers, laboratory name, contact person, telephone number and email address for receipt of results, and clinical details should accompany the sample. For suspected avian influenza a specimen submission form AND avian influenza case investigation form should be completed, forms available here (follow link [Avian influenza](#))

5.2.1 Additional considerations for sample collection

- Specimens for virus isolation or for detection of viral nucleic acids or antigens should preferably be collected within three days of onset of symptoms, but may be taken up to a week after onset or even later in children, severely ill or immunocompromised patients.
- Specimens should preferably be taken prior to commencement of antiviral therapy but can still be taken a few days after initiation, especially in patients who are deteriorating on antiviral treatment. In these cases, antiviral resistant infection should be considered and testing for oseltamivir resistant virus may be considered.
- In addition to swabs from the upper respiratory tract, invasive procedures such as bronchoalveolar lavage/bronchial aspirate or lung biopsy can be performed for the diagnosis of influenza where clinically indicated. Expecterated and induced sputum can also be tested.
- Results of all diagnostic tests for influenza are dependent upon several factors (including specimen type and quality of specimen collection, timing of collection, storage and transport conditions), such that false-negative results may be obtained. When clinical suspicion is high, clinicians can consider repeat/serial testing. Lower respiratory tract specimens may yield the diagnosis when testing of upper respiratory tract specimens is negative. Multiple respiratory tract specimens collected on different days can be tested if proof of influenza infection is important/needed.

5.2.2 Procedure for sample collection

A respiratory specimen (ideally, combined nasopharyngeal swab and oropharyngeal swab or aspirate, but a mid-turbinate nasal or oropharyngeal swab where combined sample is not possible) should be collected. Caution should be taken when collecting a nasopharyngeal swab or aspirate as these can cause aerosolisation of respiratory particles. In small children it may be easier and less traumatic to collect an aspirate rather than nasopharyngeal swab but both specimen types are acceptable and have similar diagnostic yield[30].

- Carefully label the vial of UTM with patient identification information and date of specimen collection
- Gently insert the flocked swab through one nostril beyond the anterior nares along the floor of the nasal cavity, until the pharyngeal wall is reached (swab to reach depth equal to distance from nostril to outer opening of ear)
- Do not use more than minimal force if any obstruction is encountered

- Rotate the swab three times against the nasopharyngeal wall and then withdraw the swab slowly
 - Place the swab into UTM without touching it, snap off the tip at the marked break point
 - Secure the cap
- Transport the labelled swab to the laboratory

Mid- turbinate nasal swab

- Open nasal swab: remove the nasal swab from the wrapper by pulling the two ends of the wrapper apart. Be careful to only touch the handle, not the tip (Figure 1).




Figure 1: Nasal swab

- Loosen cap on tube: slightly loosen the cap from the tube so it's easier to open later. Place it in a safe location where it won't spill – there is liquid inside (you'll be putting your swab into this tube when finished) (Figure 2).




Figure 2: Specimen collection tube

- Swab nose: Tilt head back to look at ceiling, and gently insert the soft tip of the swab into one nostril until the safety stopper touches the edge of the nostril. Gently twist the handle in a circular motion for 15 seconds. Next, gently insert the same swab into the other nostril and repeat the same 15-second procedure (Figure 3).




Figure 3: Sample collection

- Put swab in tube: Lower the swab, tip first, into the provided tube. Once the tip is at the bottom, break the swab handle at the swab breakpoint by bending back and forth. Screw the cap on tightly (Figure 4).




Figure 4: Putting swab in tube

Transport of samples to NICD

For samples that are going to be tested at NICD (see section 5.1 and 5.3), specimens should be transported within 24 hours to the Centre for Respiratory Diseases and Meningitis (CRDM), National Institute for Communicable Diseases (NICD), 1 Modderfontein Road, Sandringham, 2131. Please complete specimen submission form: click link [CRDM-specimen-submission-form](#)

6. Clinical management and considerations for treatment of influenza

Influenza is detectable in approximately 7% of children aged <5 years hospitalised with pneumonia and 9% of individuals aged ≥5 years hospitalised with pneumonia in South Africa. [31, 32]. During the influenza season, this increases to approximately 20-40% of all adults hospitalised for pneumonia.

For this reason, influenza must be considered as an important potential cause of community acquired pneumonia (CAP) in all patients during the influenza season or when there is increased influenza transmission in the community. Consideration should be given to including oseltamivir as part of empiric treatment where indicated (see section 6.1) and available. Note that because influenza vaccination is not 100% effective, a history of influenza vaccination does not exclude the possibility of influenza infection in patients with compatible clinical features.

6.1 Antiviral therapy

Antiviral medications with activity against influenza are an adjunct to influenza vaccine in the control of influenza. Few patients with influenza require treatment and initiation of treatment should be based on clinical judgment taking into consideration the patient's disease severity and progression, age, underlying medical conditions, likelihood of progressing to severe influenza, and time since onset of symptoms. When indicated, antiviral treatment should be started as early as possible, ideally within 48 hours of symptom onset, and should not be delayed while awaiting laboratory confirmation. However, antiviral treatment might still be beneficial in patients with severe, complicated or progressive illness, and in hospitalised patients when started more than 48 hours after illness onset. In alignment with WHO guidance, antiviral therapy may be considered for any patient with confirmed or suspected influenza who

- has severe/complicated illness (hospitalised patients), or
- has non-severe influenza with major risk factors for hospitalisation or mortality (see section 4.1.2).

Antiviral treatment is not indicated for treatment of influenza in persons who do not fall in the risk groups for severe influenza-associated disease and who present with non-severe/ uncomplicated influenza.

Although antivirals are recommended by the WHO for hospitalised patients and those with non-severe illness at high risk of progressing to severe illness, the evidence supporting this recommendation is low and is briefly summarised below.

Data from recent systematic reviews and meta-analysis from randomised trials reported minimal benefit from antiviral drugs for non-severe and severe influenza illness. The two systematic reviews suggest that oseltamivir and zanamivir have no effect on reducing the time to alleviation of symptoms, hospitalisation and mortality. However, baloxivir may reduce time to alleviation of symptoms and may decrease admission to hospital [33-35]. A systematic review and meta-analysis including 73 RCTs showed that compared with standard care or placebo, all antiviral drugs for treating non-severe influenza had little or no effect on hospital admission for low-risk patients. In addition, for

hospital admission in high-risk patients, oseltamivir (risk difference [RD], -0.4%; 95% CI, -1.0 to 0.4; high certainty) had little or no effect and baloxavir may have reduced risk (RD, -1.6%; 95% CI, -2.0 to 0.4; low certainty). Baloxavir probably reduced symptom duration (mean difference [MD], -1.02 days; 95% CI, -1.41 to -0.63; moderate certainty). They also reported that all antiviral drugs had little or no effect on mortality for both low-risk patients and high-risk patients. [33]. A WHO-commissioned systematic review on antivirals for treatment of patients with severe influenza, including 8 randomised trials and meta-analysis of seven trials, found low certainty evidence that oseltamivir (mean difference -1.63 days, 95% CI -2.81 to -0.45) and peramivir (-1.73 days, -3.33 to -0.13) might reduce the duration of hospitalisation in patients with severe seasonal influenza compared with placebo or standard care. Great uncertainty remained regarding the effect of oseltamivir, peramivir, and zanamivir on mortality in patients with severe seasonal influenza or zoonotic influenza. [34]

Although prospective, randomised, controlled clinical trials (RCTs) show that treatment with oseltamivir for non-severe/uncomplicated influenza illness may reduce the duration of symptoms by approximately 1 day when given within 48 hours of onset of illness [36-39], the clinical significance of this benefit and the restrictions of use within 48 hours do not strongly support treatment. A meta-analysis of individual patient data reported lower risk of mortality in patients treated with neuraminidase inhibitors compared to those not treated.[40]. Another meta-analysis showed a risk reduction in lower respiratory tract complications and in-hospital stay in the group that received oseltamivir [41].

6.1.1 Recommended antiviral medication

The neuraminidase inhibitors (oseltamivir, peramivir, and zanamivir) and cap-dependent endonuclease inhibitors (baloxavir marboxil) have activity against influenza A and B viruses, whereas the adamantanes (amantadine and rimantadine) have activity against influenza A viruses only. Oseltamivir and baloxavir (limited availability) are available in South Africa. In alignment with WHO recommendations, oseltamivir is recommended for use in hospitalised patients with suspected or confirmed severe influenza virus illness and baloxavir is recommended in patients with non-severe influenza with major risk factors for hospitalisation or mortality (see section 4.1.2) during the 2025 influenza season/ or periods of increased influenza transmission in the community. The WHO no longer recommends oseltamivir (strong recommendation, moderate quality evidence) and zanamivir (low quality evidence) for non-severe disease and zanamavir for severe influenza disease due to lack of evidence of benefit (or harm). However, despite low quality evidence the 2024 WHO guidelines

on treatment for influenza have kept the recommendation for oseltamivir in severe influenza illness. [28]. For individual patient care a risk benefit analysis may be considered by the attending clinicians. Adamantanes (amantadine and rimantadine) are not recommended for use due to high levels of resistance. The standard adult dose and duration of oseltamivir treatment is 75mg twice daily orally for 5 days. The dose for Baloxavir, 40-80 mg as single dose, depends on weight of patient. Doses for treatment are summarised in Table 1.

Table 1: Recommended dosage and duration of influenza antiviral medications for treatment

Antiviral Agent	Children	Adults
Oseltamivir (Tamiflu®)	Neonates and infants (1 day -12 months) 3mg/kg twice a day for 5 days	75 mg twice daily for 5 days
	If ≥ 1 year, dose varies by child's weight ≤15 kg, the dose is 30 mg twice a day for 5 days >15 to 23 kg, the dose is 45 mg twice a day for 5 days > 23 to 40 kg, the dose is 60 mg twice a day for 5 days >40 kg, the dose is 75 mg twice a day for 5 days	
Baloxavir (xofluzar)	5 years and older, dose varies by child's weight < 20kg, the dose is 2mg/kg oral suspension taken as a single dose 20kg-< 80 kg one 40mg tablet or 40mg (20ml) oral suspension as single dose	20 kg to < 80 kg, one 40mg tablet or 40mg (20ml) oral suspension as single dose ≥ 80kg, one 80mg tablet or 80mg (40ml) oral suspension taken as single dose

*Baloxavir may increase the risk of antiviral resistance emerging use with caution in immunocompromised. Baloxavir is not recommended for use in pregnancy and postpartum period due to lack of safety and efficacy data

Other issues regarding critical care management of patients with influenza are beyond the scope of this document. A comprehensive review appears in the journal *Critical Care Medicine* 2010 Vol. 38, No. 4(Suppl.) pp e1-e142: H1N1 Novel Influenza: Pandemic Issues for Critical Care Practitioners. Free access is available online at: <http://journals.lww.com/ccmjjournal/toc/2010/04001>

6.2 Other interventions for management

Antibiotic treatment: Antibiotics do not have a specific effect against the influenza virus but in cases of pneumonia, early empiric treatment for community-acquired pneumonia is advised because of

the high risk of secondary bacterial infection. Since there is increased risk of secondary infection with *Streptococcus pneumoniae*, *Staphylococcus aureus* and *Streptococcus pyogenes*, co-amoxiclav is a suitable empiric antibiotic.

Oxygen therapy: Monitor oxygen saturation and maintain SaO₂ >90% (92-95% for pregnant women) with nasal cannulae or facemask. High flow oxygen treatment may be required in severe cases of influenza.

Corticosteroids: Corticosteroids are not recommended for the sole indication of suspected or confirmed influenza virus infection with or at risk of severe illness. Data from observational studies, although of low quality, showed a signal of increased mortality in influenza infection treatment with steroids [42, 43]. No RCT have been conducted of corticosteroids for adjunctive immunomodulatory therapy of severe influenza virus infection.

7. Prevention of influenza

Influenza vaccination is the most effective method for prevention and control of influenza infection available currently. In general, influenza vaccines are most effective among children aged ≥ 2 years and healthy adults. A meta-analysis including data from years when there was a mismatch between vaccine and circulating strains estimated a pooled vaccine efficacy (VE) of 59% (95% CI: 51-67) in healthy adults.[44] Previous studies from South Africa have reported influenza VE estimates from 2005 to 2015 which ranged between 46% and 87% when there was a good match and ranged between -14% and 38% when the circulating A(H3N2) strain showed marked genetic drift [45, 46]. From 2020-2024, in South Africa, after adjusting for age and timing within season, the VE for any influenza in individuals of all ages was 65% (95% confidence interval (CI): 35%- 81%) in 2022, 81% (95% CI: 29%-95%) in 2023 and 72.7% (95% CI: 31.6%-89.2%) in 2024. During the same period VE for influenza A(H1N1) pdm09 was 60% (95% CI: 5%, 83%) in 2022 and 61.2% (95% CI: -11.6%-86.6%) in 2024. The VE for influenza A(H3N2) was 65% (95% CI: -1%, 88%) in 2022 and 76% (95% CI 10%-94%) in 2023. The VE for B/Victoria was 72% (95%CI: -21%, 94%) and 82.6% (95% CI:-31.6-97.7%) in 2022 and 2024, respectively [18, 47, 48]

A randomised controlled trial conducted in South Africa has shown that when pregnant women received the influenza vaccine, their risk of developing influenza illness was halved, as was the risk to their infants in the first 24 weeks of life [49]. The vaccine has been shown not only to be efficacious for prevention of influenza in both mothers and their infants, but also safe.[50-52]. Trivalent influenza vaccine has been shown to provide protection in adults living with HIV without severe immunosuppression [53]. Data are unclear as to the effectiveness in children living with HIV aged <5

years [54]. In certain groups, including the elderly, immunocompromised individuals and infants, influenza vaccine is less effective; however, it may reduce the incidence of severe disease, e.g. bronchopneumonia, hospital admission and mortality. A randomised double blind, placebo-controlled trial evaluated the efficacy of early administration (within 72 hours) of influenza vaccine after myocardial infarct (MI) or percutaneous coronary intervention (PCI) in high-risk patients with coronary artery disease. The RCT showed that compared to placebo, influenza vaccinated patients had lower risk of the composite endpoint of all-cause mortality, MI, stent thrombosis and a lower risk of all-cause death and of cardiovascular death, HR 0.72 (95%CI 0.52-0.99), 12 months after the episode [55]

7.1 Influenza vaccination

Because of the changing nature of influenza viruses, WHO continuously monitors the epidemiology and antigenic evolution of influenza viruses circulating throughout the world. Each year recommendations about strains to be included in the vaccine for the upcoming influenza season are made. Separate recommendations are made for the Southern and Northern Hemisphere vaccines each year [56].

7.1.1 Recommended influenza vaccine formulation for 2025

The following strains have been recommended for the trivalent and quadrivalent inactivated influenza vaccine (IIV) 2025 Southern Hemisphere influenza season [56]:

Egg-based tri/quadri-valent vaccines

- an A / Victoria/4897/2022 (H1N1)pdm09-like virus;
- an A/Croatia/10136RV/2023 (H3N2)-like virus;
- a B/Austria/1359417/2021 (B/Victoria lineage) like- virus; and
- a B/Phuket/3073/2013-like (B/Yamagata lineage) virus*.

*Quadrivalent vaccine is available in private sector.

These recommendations include a change to the A(H3N2) component of egg-based vaccines strains compared with the 2024 Southern Hemisphere trivalent and quadrivalent IIV. For the A(H3N2) vaccine component, the A/Thailand/8/2022-like virus was replaced with A/Croatia/10136RV/2023 (H3N2)-like virus. The WHO recommended trivalent IIV is available in the public sector (at designated clinics and hospitals). The quadrivalent IV may be available in the private sector, generally from March or April. Either trivalent- or quadrivalent- IIV may be used during 2025 depending on cost and availability at the time. As influenza B/Yamagata has not circulated for a number of years, the WHO influenza vaccine composition advisory committee maintains that the

inclusion of a B/Yamagata lineage antigen in quadrivalent influenza vaccines is no longer warranted, and every effort should be made to exclude this component as soon as possible.

7.1.2 Groups recommended for influenza vaccination

Because of limited resources and the fact that not all individuals who fall among the groups at risk for severe influenza disease respond well to influenza vaccination, the National Department of Health is prioritising certain groups of individuals. The recommendation for groups to be prioritised will be reviewed annually based on available data and resources. The following are among the groups that are prioritised for the targeted public-funded influenza vaccination campaign in 2025, these priority groups apply to both public funded vaccine and privately accessed vaccine:

- Pregnant women at all stages of pregnancy, including women up to 6 weeks postpartum
- Individuals aged ≥ 65 years
- Individuals with chronic cardiovascular disease (including chronic heart disease and stroke), diabetes, chronic lung disease (including asthma, tuberculosis and chronic obstructive pulmonary disease), chronic renal disease and individuals with immunosuppressive conditions (e.g. living with HIV or AIDS and malignancy).
- Healthcare workers

Other groups that would benefit from influenza vaccination should adequate vaccines supplies be available once the above groups have been vaccinated:

- Residents of old-age homes, chronic care and rehabilitation institutions.
- Persons aged 6 months to ≤ 18 years on long-term aspirin therapy and who therefore might be at risk for experiencing Reye syndrome after influenza virus infection.
- Individuals who are morbidly obese (body mass index ≥ 40 kg/m²).
- Adults and children who are family contacts of individuals at high risk of severe influenza.
- Any persons wishing to minimise the risk of influenza acquisition, especially in workplace settings where large-scale absenteeism could cause significant economic losses or in specific workplace settings such as industries working with live poultry that may lead to exposure to avian influenza.

Healthcare workers should also advise/inform patients where influenza vaccines are provided free of charge or provided as part of their annual medical aid benefits.

7.1.3 Contraindications to influenza vaccination

The IIV is an inactivated vaccine, and has a well-established safety record. It is safe for use in pregnancy and in children ≥ 6 months of age. Contraindications to the administration of IIV include:

- A history of severe (anaphylactic) hypersensitivity after a previous dose of any influenza vaccine. Anaphylaxis is rare and a careful history will distinguish between anaphylaxis and other allergic reactions. Egg protein allergy is not a contraindication to influenza vaccine.
- Infants <6 months of age

Precautions

- Persons with moderate illness with or without fever should preferably be immunised after symptoms have resolved.

7.1.4 Influenza vaccine dosage and administration

Influenza vaccine should be given sufficiently early to provide protection for the coming winter. A protective antibody response takes about 2 weeks to develop. The best time to vaccinate is before the influenza season starts, but getting it later will still protect during the rest of the season. Since influenza can circulate in the community outside the normal influenza season, it is never too late to vaccinate. Vaccination should continue to be offered as long as influenza viruses are circulating and a valid vaccine (before expiration date) is available. To avoid missed opportunities for vaccination, healthcare providers should offer vaccination during routine health care visits and hospitalisations, especially for patients at risk of severe influenza and its complications. Healthcare providers should offer influenza vaccination to unvaccinated persons who have already become ill with influenza during the season because the vaccine might protect them against other circulating influenza viruses.

The IIV should be administered intramuscularly (IM) as follows:

- Adults and children aged ≥ 6 years: Injection into the upper arm (deltoid).
- Children aged 1 year to <6 years: Injection into the LEFT upper arm
- Infants aged 6 months – <1 year: Injection into the LEFT antero-lateral thigh

Table 2: Recommended dosage of influenza vaccine

Age Group	Dose	Number of doses
Adults and children 9 years of age and older	Adult dose (0,5ml) IMI	Single dose
Children 3 years through 8 years	Adult dose (0,5ml) IMI	1 or 2 doses [†]

Children 6 months through 2 years	TIV 0,25ml (half the adult dose) IMI, QIV 0,5ml (adult dose) IMI	1 or 2 doses [†]
-----------------------------------	--	---------------------------

*Note: influenza vaccine is not recommended for infants <6 months of age. [†]2 doses should be administered ≥ 1 month apart during 1st year of vaccination, thereafter one dose. If QIV was administered as the first dose and is not available for the second dose, then TIV can be given.

7.2 Co-administration of influenza vaccine and childhood vaccinations in the expanded programme of immunization (EPI) and other adult vaccines

Whilst there is no contraindication to co-administration of influenza vaccine with the vaccines in the EPI programme, the South African EPI programme recommends separating the administration of measles and influenza vaccine by at least 14 days giving the measles vaccine first followed by the influenza vaccine at a later stage/visit. This is to assist with assigning the cause of the adverse event in the event that there is one.

7.3 Chemoprophylaxis of influenza

Annual influenza vaccination is the best way to prevent influenza, because vaccination can be given well before influenza virus exposures occur, and can provide safe and effective immunity throughout the influenza season. Antiviral chemoprophylaxis is currently NOT recommended. However, WHO guidelines state that individuals at extremely high risk of severe disease (≥85 years, or younger with multiple risk factors (immunocompromise, chronic disease of cardiovascular, respiratory and neurological systems, pregnancy, diabetes and malignancy) who have been exposed to a patient with seasonal influenza or any person exposed to zoonotic influenza with high mortality in humans or unknown risk of severe illness) may benefit from presumptive treatment with antivirals (e.g. in adults oseltamivir 75mg daily for 10 days, zanamivir 10mg for 10 days, baloxivir, 40-80 mg as single dose), even if they do not show signs and symptoms of infection[28]. Alternatively, such patients can be monitored closely for early signs of possible influenza infection, and given antiviral treatment if they occur. [28, 57]

7.4 To prevent transmission of influenza to others, patients should:

- Stay at home until symptoms have resolved (at least 24 hours after fever has defervesced)
- Avoid close contact with others especially those at high risk for severe influenza (see section 4.1.1 for individuals at risk of severe influenza)
- Avoid close contact such as kissing or sharing drinks
- Cover coughs and sneezes (cover mouth and nose with tissue or cough or sneeze into an elbow)

- Wear a tight fitting mask especially in public places
- Wash hands with soap and water or disinfect with an alcohol-based hand rub regularly
- Wipe down surfaces that are frequently touched or shared (doorknobs, remote controls) with a standard household disinfectant

8. Infection prevention and control (IPC) considerations

Human-to-human transmission of influenza viruses occurs either directly or indirectly through close, unprotected contact with large respiratory droplets. The role of smaller droplet nuclei at close-range exposure in transmission of influenza is not known, but may be more important in certain settings (e.g. aerosol-generating procedures associated with increased risk of virus transmission). Collection of nasopharyngeal swabs and aspirates is considered as aerosol generating.

Therefore, IPC precautions need to be focused on controlling respiratory droplet spread.

When working in direct contact with patients, standard and droplet precautions should be applied. Recommended IPC precautions when caring for patients with suspected or confirmed influenza include:

- Standard precautions:
 - Hand hygiene: washing hands with soap and water or the use of an alcohol-based hand rub
 - Use of personal protective equipment (PPE): this includes facial protection (by means of a medical mask and eye-visor/goggles or a face shield) as well as use of a gown and clean gloves
- Droplet precautions:
 - Wear a medical mask if working within approximately 1 metre of the patient or upon entering the room/cubicle of a patient on droplet precautions
 - Perform hand hygiene before and after patient contact and immediately on removal of a medical mask
- IPC precautions when performing aerosol-generating procedures associated with an increased risk of infection transmission (e.g. aspiration/open suctioning of the respiratory tract, including for the collection of respiratory tract specimens, intubation, resuscitation, bronchoscopy, autopsy):
 - Wear a particulate respirator (e.g. fit-tested N95 respirator), a clean non-sterile long-sleeved gown, and gloves
 - Perform hand hygiene before and after patient contact and after PPE removal

- IPC precautions for patients who are mechanically ventilated or undergoing respiratory therapy:
 - Mechanically ventilated patients: Standard and droplet precautions (but when aerosol-generating procedures are performed, particulate respirators need to be worn)
 - Chest physiotherapy: Standard and droplet precautions. A medical mask should be worn by the patient if possible
- Nebulisation: Standard and droplet precautions.

9. Public Health Response to influenza

Influenza epidemics occur each year during the winter season. Vaccination of high-risk groups and individuals wishing to protect themselves against influenza is recommended prior to the expected start of the annual influenza season. No public health response is required in response to isolated cases of influenza or outbreaks of mild disease especially in the influenza season.

9.1 Outbreaks should be investigated in the following circumstances:

- A cluster of two or more cases of severe respiratory illness (requiring hospitalisation)
- An outbreak in a closed community e.g. care home, school, healthcare facility, where individuals in the community are at substantial increased risk of severe disease, or the outbreak is causing substantial disruption.
- An outbreak among individuals working with live poultry who present with symptoms consistent with influenza like illness.

9.1.1 During an outbreak in a closed or semi-closed community the following measures should be considered:

- Isolation of residents of closed settings for the duration of the infectious period (five days after symptom onset).
- Cohorting of patients (that is, in separate hospital bays or on separate floors of a residential home, dormitories) may be necessary.
- Residential homes may need to be closed to new admissions until the outbreak is controlled.
- Care must be taken when discharging a patient from a ward with a known influenza outbreak to a care home, or vice versa.
- Full or partial school closures are not generally recommended on public health grounds, although it is recognized that they may be considered on logistical grounds by the school.

- Administer the current season's influenza vaccine to unvaccinated residents and health care personnel. It is important to note though that because influenza spreads fast it is possible that it will be widespread by the time an outbreak is identified and therefore vaccination may not be effective.

10. References

1. Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius M, *et al.* Mortality amongst Patients with Influenza-Associated Severe Acute Respiratory Illness, South Africa, 2009-2013. *PLoS One* 2015,**10**:e0118884.
2. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, *et al.* Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. *Lancet* 2011,**378**:1917-1930.
3. World Health Organization. Seasonal influenza. In. WHO website 2016.
4. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, *et al.* Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. *The Lancet*,**391**:1285-1300.
5. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. *Lancet* 2011,**377**:1264-1275.
6. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, *et al.* Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. *Lancet Infect.Dis.* 2012,**12**:687-695.
7. Cohen C, Simonsen L, Kang JW, Miller M, McAnerney J, Blumberg L, *et al.* Elevated influenza-related excess mortality in South African elderly individuals, 1998-2005. *Clin.Infect.Dis.* 2010,**51**:1362-1369.
8. Tempia S, Walaza S, Moyes J, Cohen AL, McMorrow ML, Treurnicht FK, *et al.* Quantifying How Different Clinical Presentations, Levels of Severity, and Healthcare Attendance Shape the Burden of Influenza-associated Illness: A Modeling Study From South Africa. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2019,**69**:1036-1048.
9. Tempia S, Walaza S, Viboud C, Cohen AL, Madhi SA, Venter M, *et al.* Deaths Associated with Respiratory Syncytial and Influenza Viruses among Persons ≥ 5 Years of Age in HIV-Prevalent Area, South Africa, 1998-2009. *Emerg Infect Dis* 2015,**21**:600-608.
10. Tempia S, Walaza S, Cohen AL, von Mollendorf C, Moyes J, McAnerney JM, *et al.* Mortality Associated with Seasonal and Pandemic Influenza among Pregnant and Non-Pregnant Women of Childbearing Age in a High HIV Prevalence Setting – South Africa, 1999-2009. *Clinical Infectious Diseases* 2015.
11. Tempia S, Walaza S, Viboud C, Cohen AL, Madhi SA, Venter M, *et al.* Mortality associated with seasonal and pandemic influenza and respiratory syncytial virus among children < 5 years of age in a high HIV prevalence setting--South Africa, 1998-2009. *Clin.Infect.Dis.* 2014,**58**:1241-1249.
12. Cohen C, Moyes J, Tempia S, Groom M, Walaza S, Pretorius M, *et al.* Severe influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009-2011. *Emerg.Infect.Dis.* 2013,**19**:1766-1774.
13. Murray J, Cohen A, Walaza S, Groome M, Madhi S, Variava E, *et al.* Determining the Provincial and National Burden of Influenza-Associated Severe Acute Respiratory Illness in South Africa Using a Rapid Assessment Methodology. *PLoS One* 2015,**10**:e0132078.
14. Tempia S, Walaza S, Moyes J, Cohen AL, von Mollendorf C, Treurnicht FK, *et al.* Risk Factors for Influenza-Associated Severe Acute Respiratory Illness Hospitalization in South Africa, 2012–2015. *Open Forum Infectious Diseases* 2017,**4**:ofw262-ofw262.
15. Walaza S, Cohen C, Nanoo A, Cohen AL, McAnerney J, von Mollendorf C, *et al.* Excess Mortality Associated with Influenza among Tuberculosis Deaths in South Africa, 1999-2009. *PLoS One* 2015,**10**:e0129173.

16. Walaza S, Tempia S, Dawood H, Variava E, Moyes J, Cohen AL, *et al.* Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa, 2010-2011. *BMC Infect Dis* 2015,**15**:26.
17. Tempia S, Walaza S, Moyes J, McMorro ML, Cohen AL, Edoka I, *et al.* Influenza disease burden among potential target risk groups for immunization in South Africa, 2013-2015. *Vaccine* 2020,**38**:4288-4297.
18. Nicole Wolter AB, Sibongile Walaza, Jocelyn Moyes, Mvuyo Makhasi, Jackie, Kleynhans JY, Mignon du Plessis, Fahima Moosa, Dikeledi Kekana, Anele Mnguni,, Lorens Maake LdG, Cheryl Cohen, and Anne von Gottberg. Influenza surveillance in South Africa, weeks 1 to 52, 2024. In: National Institute for Communicable Diseases; 2025.
19. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. *Lancet Infect.Dis.* 2009,**9**:493-504.
20. Public Health England. PHE guidance on use of antiviral agents for the treatment and prophylaxis of influenza (2014-15). In; 2015. pp. 1-23.
21. Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, *et al.* Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. *PLoS.Med.* 2011,**8**:e1001053.
22. Louie JK, Salibay CJ, Kang M, Glenn-Finer RE, Murray EL, Jamieson DJ. Pregnancy and severe influenza infection in the 2013-2014 influenza season. *Obstet Gynecol* 2015,**125**:184-192.
23. Cohen C, Simonsen L, Sample J, Kang JW, Miller M, Madhi SA, *et al.* Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. *Clin Infect Dis.* 2012,**55**:996-1003.
24. Angelo SJ, Marshall PS, Chrissoheris MP, Chaves AM. Clinical characteristics associated with poor outcome in patients acutely infected with Influenza A. *Conn Med* 2004,**68**:199-205.
25. Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. *Diabetes Care* 2010,**33**:1491-1493.
26. Puvanalingam A, Rajendiran C, Sivasubramanian K, Ragunanthanan S, Suresh S, Gopalakrishnan S. Case series study of the clinical profile of H1N1 swine flu influenza. *J.Assoc.Physicians India* 2011,**59**:14-16, 18.
27. Fezeu L, Julia C, Henegar A, Bitu J, Hu FB, Grobbee DE, *et al.* Obesity is associated with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis. *Obes Rev* 2011,**12**:653-659.
28. World Health Organization. Clinical practice guidelines for influenza. In. Geneva: World Health Organization; 2024.
29. Daley P, Castriciano S, Chernesky M, Smieja M. Comparison of flocked and rayon swabs for collection of respiratory epithelial cells from uninfected volunteers and symptomatic patients. *J Clin Microbiol* 2006,**44**:2265-2267.
30. Heikkinen T, Marttila J, Salmi AA, Ruuskanen O. Nasal Swab versus Nasopharyngeal Aspirate for Isolation of Respiratory Viruses. *Journal of Clinical Microbiology* 2002,**40**:4337-4339.
31. Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, *et al.* Epidemiology of Viral-associated Acute Lower Respiratory Tract Infection Among Children <5 Years of Age in a High HIV Prevalence Setting, South Africa, 2009-2012. *Pediatr Infect Dis J* 2015,**34**:66-72.
32. Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, *et al.* Epidemiology of Severe Acute Respiratory Illness (SARI) among Adults and Children Aged >=5 Years in a High HIV-Prevalence Setting, 2009-2012. *PLoS One* 2015,**10**:e0117716.
33. Gao Y, Zhao Y, Liu M, Luo S, Chen Y, Chen X, *et al.* Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis. *JAMA Internal Medicine* 2025,**185**:293-301.
34. Gao Y, Guyatt G, Uyeki TM, Liu M, Chen Y, Zhao Y, *et al.* Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. *The Lancet* 2024,**404**:753-763.

35. Baghdadi JD, Grady D, Morgan DJ. The Limited Role for Antiviral Therapy in Influenza. *JAMA Internal Medicine* 2025,**185**:301-301.
36. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, *et al.* Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. *Lancet* 2000,**355**:1845-1850.
37. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, *et al.* Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. *J Infect Dis* 1999,**180**:254-261.
38. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, *et al.* Oral oseltamivir treatment of influenza in children. *Pediatr Infect Dis J* 2001,**20**:127-133.
39. Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2018,**66**:1492-1500.
40. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al MA, *et al.* Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. *Lancet Respir. Med.* 2014,**2**:395-404.
41. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. *Lancet* 2015,**385**:1729-1737.
42. Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. *Critical Care Medicine* 2020,**48**:e98-e106.
43. Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. *Cochrane Database Syst Rev* 2019,**2**:Cd010406.
44. Osterholm M, Kelley N, Sommer A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2012,**12**:36 - 44.
45. McAnerney JM, Treurnicht F, Walaza S, Cohen AL, Tempia S, Mtshali S, *et al.* Evaluation of influenza vaccine effectiveness and description of circulating strains in outpatient settings in South Africa, 2014. *Influenza Other Respir Viruses* 2015,**9**:209-215.
46. Ntshoe GM, McAnerney JM, Tempia S, Blumberg L, Moyes J, Buys A, *et al.* Influenza epidemiology and vaccine effectiveness among patients with influenza-like illness, viral watch sentinel sites, South Africa, 2005-2009. *PLoS One* 2014,**9**:e94681.
47. Nicole Wolter AB, Sibongile Walaza, Jocelyn Moyes, Mvuyo Makhasi, Jackie, Kleynhans JY, Mignon du Plessis, Fahima Moosa, Dikeledi Kekana, Anele Mnguni,, Lorens Maake LdG, Cheryl Cohen and Anne von Gottberg. Influenza Surveillance in South Africa, Week 1 to 34, 2023. In. Public Health Bulletin South Africa: National Institute for Communicable Diseases; 2024.
48. Nicole Wolter AB, Sibongile Walaza, Jocelyn Moyes, Mignon du Plessis, Thulisa, Mkhencele FM, Daniel Amoako, Dikeledi Kekana, Linda de Gouveia, Cheryl Cohen, Gottberg aAv. INFLUENZA SURVEILLANCE IN SOUTH AFRICA: WEEKS 1 - 32, 2022. In. Johannesburg , South Africa: National Institute for Communicable Diseases; 2023.
49. Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, *et al.* Influenza vaccination of pregnant women and protection of their infants. *N Engl J Med* 2014,**371**:918-931.
50. Madhi SA, Nunes MC, Cutland CL. Influenza vaccination of pregnant women and protection of their infants. *N Engl J Med* 2014,**371**:2340.
51. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, *et al.* Effectiveness of Maternal Influenza Immunization in Mothers and Infants. *New England Journal of Medicine* 2008,**359**:1555-1564.

52. Eick AA, Uyeki TM, Klimov A, Hall H, Reid R, Santosham M, *et al.* Maternal influenza vaccination and effect on influenza virus infection in young infants. *Arch Pediatr Adolesc Med* 2011,**165**:104-111.
53. Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, *et al.* Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. *Clin Infect Dis.* 2011,**52**:128-137.
54. Madhi SA, Dittmer S, Kuwanda L, Venter M, Cassim H, Lazarus E, *et al.* Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. *Aids* 2013,**27**:369-379.
55. Fröbert O, Götberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, *et al.* Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. *Circulation* 2021,**144**:1476-1484.
56. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2025 southern hemisphere influenza season. In. Geneva: World Health Organization; 2024.
57. World Health Organization. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses. In; 2010. pp. 32.